Literature DB >> 15335301

Sexual dysfunction associated with antidepressant drugs.

David S Baldwin1.   

Abstract

The term 'sexual dysfunction' describes a disturbance in sexual desire and the psychophysiological changes that characterise the normal sexual response cycle, and cause marked personal distress and interpersonal difficulty. Epidemiological studies indicate that sexual dysfunction is common in the general population, but more common in depressed individuals in community settings and clinical samples. Most antidepressant drugs have adverse effects on sexual function, but accurate identification of the incidence of treatment-emergent dysfunction has proved troublesome. Futhermore, investigations of sexual dysfunction associated with antidepressants have one or more methodological flaws. There may be some advantages for bupropion, moclobemide, nefazodone and reboxetine over other antidepressants. Many approaches have been adopted for management of patients with sexual dysfunction associated with antidepressant treatment, including waiting for the problem to resolve, behavioural strategies to modify sexual technique, individual and couple psychotherapy, delaying the intake of antidepressants until after sexual activity, reduction in daily dosage, 'drug holidays', use of adjuvant treatments, and switching to a different antidepressant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15335301     DOI: 10.1517/14740338.3.5.457

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  15 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  Impact of Antidepressant Drugs on Sexual Function and Satisfaction.

Authors:  David S Baldwin; Chris Manson; Magda Nowak
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

3.  Effects of bupropion on the ejaculatory response of male rats.

Authors:  M E Hueletl-Soto; M Carro-Juárez; G Rodríguez-Manzo
Journal:  Int J Impot Res       Date:  2014-05-01       Impact factor: 2.896

4.  The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.

Authors:  Angel L Montejo; Laura Montejo; David S Baldwin
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

Review 5.  Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

Authors:  Narayan D Chaurasiya; Francisco Leon; Ilias Muhammad; Babu L Tekwani
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

6.  Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting.

Authors:  Kyoung-Uk Lee; Young Min Lee; Ji-Min Nam; Hae-Kook Lee; Yong-Sil Kweon; Chung Tai Lee; Tae-Youn Jun
Journal:  Psychiatry Investig       Date:  2010-02-08       Impact factor: 2.505

7.  A primary analysis of sexual problems in Chinese patients with ankylosing spondylitis.

Authors:  Biyu Shen; Aixian Zhang; Jinwei Liu; Zhanyun Da; Xujuan Xu; Zhifeng Gu
Journal:  Rheumatol Int       Date:  2012-11-15       Impact factor: 2.631

8.  Sexual problems in male ankylosing spondylitis patients: relationship with functionality, disease activity, quality of life, and emotional status.

Authors:  Engin Cakar; Umit Dincer; Mehmet Zeki Kiralp; Mehmet Ali Taskaynatan; Evren Yasar; Emine Ozgur Bayman; Ahmet Ozgul; Hasan Dursun
Journal:  Clin Rheumatol       Date:  2007-02-07       Impact factor: 2.980

9.  Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants.

Authors:  David S Baldwin; M Carlotta Palazzo; Vasilios G Masdrakis
Journal:  Depress Res Treat       Date:  2013-02-04

10.  Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.

Authors:  Carl Gommoll; Giovanna Forero; Maju Mathews; Rene Nunez; Xiongwen Tang; Suresh Durgam; Angelo Sambunaris
Journal:  Int Clin Psychopharmacol       Date:  2015-11       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.